Associations of pregnancy-related factors and birth characteristics with risk of endometrial cancer: A Nordic population-based case-control study.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 03 2020
Historique:
received: 13 12 2018
revised: 06 05 2019
accepted: 23 05 2019
pubmed: 8 6 2019
medline: 13 2 2020
entrez: 8 6 2019
Statut: ppublish

Résumé

Many pregnancy-related factors are associated with reduced endometrial cancer risk. However, it remains unclear whether pregnancy-related complications (e.g., hypertensive conditions) are associated with risk and whether these associations vary by endometrial cancer subtype. Thus, we evaluated the risk of endometrial cancer, overall and by subtype, in relation to pregnancy-related factors, pregnancy complications and birth characteristics. Utilizing population-based register data from four Nordic countries, we conducted a nested case-control analysis of endometrial cancer risk. We included 10,924 endometrial cancer cases and up to 10 matched controls per case. Odds ratios (ORs) with 95% confidence intervals (CIs) were derived from unconditional logistic regression models. We further evaluated associations by individual histology (i.e., endometrioid, serous, etc.) or, for rare exposures (e.g., pregnancy complications), by dualistic type (Type I [n = 10,343] and Type II [n = 581]). Preexisting and pregnancy-related hypertensive conditions were associated with increased endometrial cancer risk (OR [95% CI]: preexisting hypertension 1.88 [1.39-2.55]; gestational hypertension 1.47 [1.33-1.63]; preeclampsia 1.43 [1.30-1.58]), with consistent associations across dualistic type. Increasing number of pregnancies (≥4 vs. 1 birth: 0.64 [0.59-0.69]) and shorter time since last birth (<10 vs. ≥30 years: 0.34 [0.29-0.40]) were associated with reduced endometrial cancer risk, with consistent associations across most subtypes. Our findings support the role for both hormonal exposures and cell clearance as well as immunologic/inflammatory etiologies for endometrial cancer. This research supports studying endometrial hyperplasia, a precursor condition of endometrial cancer, in the context of pregnancy-related exposures, as this may provide insight into the mechanisms by which pregnancy affects subsequent cancer risk.

Identifiants

pubmed: 31173648
doi: 10.1002/ijc.32494
pmc: PMC6898733
mid: NIHMS1039805
doi:

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1523-1531

Subventions

Organisme : Intramural NIH HHS
ID : ZIA CP010126-21
Pays : United States

Informations de copyright

Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Références

Am J Epidemiol. 2013 Jan 15;177(2):142-51
pubmed: 23171881
Mol Cell Endocrinol. 2018 Apr 15;465:48-60
pubmed: 28919297
Int J Cancer. 2017 Feb 1;140(3):600-610
pubmed: 27770434
Acta Obstet Gynecol Scand. 2015 Jul;94(7):701-707
pubmed: 25867490
Am J Obstet Gynecol. 2009 Jan;200(1):63.e1-5
pubmed: 18822400
Acta Obstet Gynecol Scand. 2013 Aug;92(8):943-50
pubmed: 23621424
Am J Epidemiol. 2012 Aug 15;176(4):269-78
pubmed: 22831825
Eur J Cancer. 2009 May;45(7):1218-1231
pubmed: 19091545
Br J Cancer. 2016 Nov 22;115(11):1416-1420
pubmed: 27701386
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Hum Reprod Update. 2014 Sep-Oct;20(5):748-58
pubmed: 24688118
Int J Cancer. 2018 Oct 15;143(8):1904-1913
pubmed: 29752724
Int J Cancer. 2010 Jan 1;126(1):208-16
pubmed: 19551854
Cancer Causes Control. 2009 Oct;20(8):1441-9
pubmed: 19565342
J Clin Oncol. 2013 Jul 10;31(20):2607-18
pubmed: 23733771
Eur J Obstet Gynecol Reprod Biol. 2013 Dec;171(2):333-8
pubmed: 24094821
Clin Med Insights Blood Disord. 2018 Jan 10;11:1179545X17752325
pubmed: 29371787
Br J Cancer. 2016 Mar 29;114(7):809-12
pubmed: 26964032
Int J Cancer. 2010 Jul 15;127(2):442-51
pubmed: 19924816
Acta Oncol. 2009;48(1):27-33
pubmed: 18767000
Acta Obstet Gynecol Scand. 2008;87(11):1123-8
pubmed: 18951203
J Clin Oncol. 2004 Jul 15;22(14):2842-8
pubmed: 15254051
Tidsskr Nor Laegeforen. 2017 Sep 04;137(16):
pubmed: 28871734
Scand J Public Health. 2011 Jul;39(7 Suppl):42-5
pubmed: 21775350
Acta Obstet Gynecol Scand. 2009;88(1):52-8
pubmed: 19140043
Int J Cancer. 2018 Oct 15;143(8):1858-1867
pubmed: 29737528
Eur J Cancer. 2017 May;77:31-39
pubmed: 28350996
Epidemiology. 2011 Sep;22(5):638-45
pubmed: 21691206
J Intern Med. 2018 May;283(5):430-445
pubmed: 29476569
Gynecol Oncol. 2016 Feb;140(2):352-8
pubmed: 26701413

Auteurs

Britton Trabert (B)

Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Rebecca Troisi (R)

Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Tom Grotmol (T)

Cancer Registry of Norway, Oslo, Norway.

Anders Ekbom (A)

Department of Medicine, Division of Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden.

Anders Engeland (A)

Division of Mental and Physical Health, Norwegian Institute of Public Health, Bergen, Norway.
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.

Mika Gissler (M)

Information Services Department, National Institute for Health and Welfare (THL), Helsinki, Finland.
Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.

Ingrid Glimelius (I)

Department of Medicine, Division of Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden.
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Laura Madanat-Harjuoja (L)

Cancer Society of Finland, Finnish Cancer Registry, Helsinki, Finland.
Department of Pediatrics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Henrik Toft Sørensen (HT)

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Steinar Tretli (S)

Cancer Registry of Norway, Oslo, Norway.

Anne Gulbech Ording (A)

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Tone Bjørge (T)

Cancer Registry of Norway, Oslo, Norway.
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH